

Product Data Sheet

SKI-I

Cat. No.:HY-115735CAS No.:306301-68-8Molecular Formula: $C_{25}H_{18}N_4O_2$ Molecular Weight:406.44

Target: SphK; Apoptosis

Pathway: Immunology/Inflammation; Apoptosis

Storage: 4°C, protect from light

* In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

SOLVENT & SOLUBILITY

In Vitro DMSO: 100 mg/mL (246.04 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.4604 mL	12.3019 mL	24.6039 mL
	5 mM	0.4921 mL	2.4604 mL	4.9208 mL
	10 mM	0.2460 mL	1.2302 mL	2.4604 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo 1. Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: \geq 2.5 mg/mL (6.15 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	SKI-I is a potent and selective inhibitor of human sphingosine kinase (SK), with an IC $_{50}$ of 1.2 μ M for ST-hSK. SKI-I also inhibits hERK2 (IC $_{50}$ =11 μ M). SKI-I induces apoptosis in tumor cell lines ^{[1][2]} .
IC ₅₀ & Target	IC50: 1.2 μ M (ST-hSK); 11 μ M (hERK2) ^[1]
In Vitro	SKI-I (Compound I; $5 \mu g/mL$) inhibits SK activity by $99\%^{[1]}$. SKI-I ($10 \mu M$; $24 h$) induces the apoptosis of T24 cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. French KJ, et, al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 2003 Sep 15;63(18):5962-9.

2]. Sharma AK, et, al. Synthesis	and bioactivity of sphingosine	kinase inhibitors and their novel	aspirinyl conjugated analogs. Eur J Med Chem.	2010 Sep;45(9):4149-56.
	Caution: Product has not	been fully validated for media	cal applications. For research use only.	
	Tel: 609-228-6898 Address: 1 De	Fax: 609-228-5909 eer Park Dr, Suite Q, Monmout	E-mail: tech@MedChemExpress.com h Junction, NJ 08852, USA	

Page 2 of 2 www.MedChemExpress.com